SkinHealth Q3: Net Loss Narrows to $0.9M, But $250M 2028 Notes Need Refinancing
SKIN is trading near its 52-week low of $9.68 (6.9% above the low).
Summary
SkinHealth's Q3 net loss shrank to $0.9M from $11.0M on a 68.2% gross margin, but cash dropped to $112.4M after retiring the 2026 notes, and management says the $250M of 2028 notes will need refinancing.
Key Events · Earnings and Guidance · SKIN
-
Q3 Net Loss Narrows Sharply
Net sales fell 2.1% to $69.2M, but gross margin rose to 68.2% from 64.6% and operating income swung to $5.0M from a $6.2M loss, cutting the net loss to $0.9M from $11.0M.
-
Cash Falls After 2026 Notes Retired
Cash, cash equivalents and restricted cash dropped to $112.4M from $232.7M at December 31, 2025, after the company repaid the remaining $103.2M of 2026 Notes on September 30, 2026.
-
$250M 2028 Notes Need Refinancing
The $250.0M of 7.95% convertible notes due November 15, 2028 exceed the $112.4M cash balance; management says satisfaction at maturity will require refinancing, restructuring or other additional capital, with no assurance of acceptable terms.
-
Securities Settlement Mostly Insured
An $18.0M cash settlement payment is due into escrow by November 5, 2026, of which only $3.0M comes from company funds and $15.0M from insurers; final court approval hearing is December 9, 2026.
Analysis · SKIN · Industrial Applications And Services
The quarter itself marks a genuine turnaround on the cost line: gross margin rose to 68.2% from 64.6% and operating income swung to $5.0M from a $6.2M loss, cutting the net loss to $0.9M from $11.0M. The balance sheet is the concern. Cash fell to $112.4M from $232.7M at year-end, largely because the company retired the remaining $103.2M of 2026 Notes on September 30. That leaves $250.0M of 7.95% notes due November 15, 2028, and management states plainly that satisfying them will require refinancing, restructuring or other additional capital. With $112.4M of cash against that maturity, the refinancing is the real story behind the improved P&L. Separately, the $18.0M securities settlement is mostly insurer-funded — only $3.0M comes from company funds — with a final approval hearing set for December 9, 2026.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2653 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKIN was trading at $10.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $9.68 to $34.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.